France
Mablink Bioscience
Mablink aims to transform the immunotherapy of cancers with its next generation Antibody-Drug Conjugates (ADC), leveraging PSARlinkā¢, its innovative proprietary hydrophilic drug-linker platform.
Mablink is developing its own pipeline of ADCs.
